{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.07","upperLimit":"0.38","value":"0.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The primary endpoint of this phase II trial is the proportion of confirmed responses (complete response (CR) or partial response (PR)) noted as the objective status and will be considered synonymous with \"success\" for this study.Response will be evaluated using all cycles of treatment. A CR is defined using the Cheson et al. Revised Response Criteria for Malignant Lymphoma as Disappearance of all evidence of disease. A PR is defined as Regression of measurable disease and no new sites with ≥50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral 40 mg panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (LBH589)"}],"paramType":"NUMBER","populationDescription":"Patients who completed the study were evaluable for the primary outcome. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.","reportingStatus":"POSTED","timeFrame":"Every 28 days for up to 2 years","title":"Proportion of Confirmed Responses Defined to be a CR or PR Noted as the Objective Status","type":"PRIMARY","unitOfMeasure":"proportion of CR or PR patients"}